Cladribine impedes in vitro migration of mononuclear cells: A possible implication for treating multiple sclerosis

European Journal of Neurology

Volumn 16, Issue 3, 2009, Pages 409-412

  Kopadze, T ^a   Dobert M ^a   Leussink, V I ^a   Dehmel, T ^a   Kieseier, B C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Blood brain barrier; Immunosuppression; Matrix metalloproteinases; Multiple sclerosis; Therapy

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CLADRIBINE; GELATINASE A; GELATINASE B;

ADULT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL ISOLATION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MALE; MICROSCOPY; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADULT; ANTIGENS, CD14; ANTIGENS, CD4; ANTIGENS, CD8; CELL MOVEMENT; CLADRIBINE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MONOCYTES; MULTIPLE SCLEROSIS; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES;

EID: 60049093599     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02433.x     Document Type: Article

References (14)

1. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992 340 : 952 956.
2. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000 54 : 1145 1155.
3. Langtry HD, Lamb HM. Cladribine: a review of its use in multiple sclerosis. BioDrugs 1998 9 : 419 433.
4. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007 21 : 483 502.
5. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology 2000 47 : 707 717.
6. Compston A, Coles A. Multiple sclerosis. Lancet 2002 359 : 1221 1231.
7. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nature Reviews. Neuroscience 2001 2 : 502 511.
8. Kopadze T, Dehmel T, Hartung HP, et al. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Archives of Neurology 2006 63 : 1572 1578.
9. Chow KU, Ries J, Weidmann E, et al. Induction of apoptosis using 2′,2′ difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Annals of Hematology 2000 79 : 485 492.
10. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Annals of Neurology 1996 40 : 853 863.
11. Kopadze T, Dehmel T, Mylius HA, et al. Treosulfan impedes the migration of immunocompetent cells. Journal of Neurology 2007 254 : 1457 1458.
12. Liliemark J, Peterson C. Purine analogs and antifolates. In : Schellers JHM, McLeod HL, Newell DR, eds. Cancer Clinical Pharmacology. Oxford : Oxford University Press, 2005 : 63 83.
13. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Review of Neurotherapeutics 2005 5 : 721 727.
14. Martinez-Rodriguez JE, Cadavid D, Wolansky LJ, Pliner L, Cook SD. Cladribine in aggressive forms of multiple sclerosis. European Journal of Neurology 2007 14 : 686 689.